ArticleJournal of translational medicine2025
The TP53-LGALS4 axis modulates the tumor immune microenvironment and synergizes with anti PD-L1 therapy in colorectal cancer.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Pan-cancer 8q24 amplification predicts primary immunotherapy resistance and therapeutic vulnerabilities.iScience · 2026Article
- Galectins at the crossroads of tumor immunity, metabolism, and metastasis: mechanisms, therapeutic resistance, and translational opportunities.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundThe role of galectin-4 (LGALS4) in colorectal cancer (CRC) progression and the tumor immune microenvironment (TIME) is poorly understood.
methodsThrough analysis of single-cell profiling data from various colon tissues, this work identifies tumor suppressor genes critically involved in CRC development. The impact of LGALS4 on CT26 cell growth was evaluated through a combination of in vitro and in vivo experiments. The potential mechanisms regulating LGALS4 expression and LGALS4 regulatory biological functions were investigated using different analytical and detection assays. In vivo experiments evaluated the synergistic anti-tumor effect of LGALS4 overexpression and PDL1 neutralizing antibody.
resultsThis study revealed that the expression of LGALS4 was significantly reduced in clinical CRC tissue samples. Multimodal analysis combined with experimental verification suggested that TP53 mutations might mediate the downregulation of LGALS4 expression. Functional studies indicated that overexpression of LGALS4 did not affect the biological functions of CT26 cells, such as proliferation, apoptosis, and migration, but significantly inhibited the growth of subcutaneous transplanted tumor. Mechanistically, LGALS4 exerts its effect by improving the TIME. Specifically, it activates the CCL4/CCR5 axis through the NF-κB signaling pathway, thereby promoting the recruitment of various immune cells, including macrophages. Moreover, overexpression of LGALS4 can synergistically enhance anti-tumor effects with PD-L1 neutralizing antibodies.
conclusionCollectively, these findings demonstrate a novel role for TP53-mediated LGALS4 in regulating tumor progression. This work identifies LGALS4 as a promising therapeutic target and provides a foundation for the development of combined immunotherapy based on galectin for CRC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.